IBDEI2LV ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41616,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41616,1,3,0)
 ;;=3^Dysphasia following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,41616,1,4,0)
 ;;=4^I69.821
 ;;^UTILITY(U,$J,358.3,41616,2)
 ;;=^5007523
 ;;^UTILITY(U,$J,358.3,41617,0)
 ;;=I69.221^^155^2061^25
 ;;^UTILITY(U,$J,358.3,41617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41617,1,3,0)
 ;;=3^Dysphasia following oth nontraumatic intracranial hemorrhage
 ;;^UTILITY(U,$J,358.3,41617,1,4,0)
 ;;=4^I69.221
 ;;^UTILITY(U,$J,358.3,41617,2)
 ;;=^5007460
 ;;^UTILITY(U,$J,358.3,41618,0)
 ;;=G11.1^^155^2061^27
 ;;^UTILITY(U,$J,358.3,41618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41618,1,3,0)
 ;;=3^Early-onset cerebellar ataxia
 ;;^UTILITY(U,$J,358.3,41618,1,4,0)
 ;;=4^G11.1
 ;;^UTILITY(U,$J,358.3,41618,2)
 ;;=^5003753
 ;;^UTILITY(U,$J,358.3,41619,0)
 ;;=I69.392^^155^2061^28
 ;;^UTILITY(U,$J,358.3,41619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41619,1,3,0)
 ;;=3^Facial weakness following cerebral infarction
 ;;^UTILITY(U,$J,358.3,41619,1,4,0)
 ;;=4^I69.392
 ;;^UTILITY(U,$J,358.3,41619,2)
 ;;=^5007517
 ;;^UTILITY(U,$J,358.3,41620,0)
 ;;=I69.192^^155^2061^29
 ;;^UTILITY(U,$J,358.3,41620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41620,1,3,0)
 ;;=3^Facial weakness following nontraumatic intcrbl hemorrhage
 ;;^UTILITY(U,$J,358.3,41620,1,4,0)
 ;;=4^I69.192
 ;;^UTILITY(U,$J,358.3,41620,2)
 ;;=^5007454
 ;;^UTILITY(U,$J,358.3,41621,0)
 ;;=I69.292^^155^2061^31
 ;;^UTILITY(U,$J,358.3,41621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41621,1,3,0)
 ;;=3^Facial weakness following oth nontraumatic intcrn hemorrhage
 ;;^UTILITY(U,$J,358.3,41621,1,4,0)
 ;;=4^I69.292
 ;;^UTILITY(U,$J,358.3,41621,2)
 ;;=^5007486
 ;;^UTILITY(U,$J,358.3,41622,0)
 ;;=I69.092^^155^2061^30
 ;;^UTILITY(U,$J,358.3,41622,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41622,1,3,0)
 ;;=3^Facial weakness following ntrm subarachnoid hemorrhage
 ;;^UTILITY(U,$J,358.3,41622,1,4,0)
 ;;=4^I69.092
 ;;^UTILITY(U,$J,358.3,41622,2)
 ;;=^5007422
 ;;^UTILITY(U,$J,358.3,41623,0)
 ;;=I69.892^^155^2061^32
 ;;^UTILITY(U,$J,358.3,41623,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41623,1,3,0)
 ;;=3^Facial weakness following other cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,41623,1,4,0)
 ;;=4^I69.892
 ;;^UTILITY(U,$J,358.3,41623,2)
 ;;=^5007548
 ;;^UTILITY(U,$J,358.3,41624,0)
 ;;=I69.351^^155^2061^34
 ;;^UTILITY(U,$J,358.3,41624,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41624,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right dominant side
 ;;^UTILITY(U,$J,358.3,41624,1,4,0)
 ;;=4^I69.351
 ;;^UTILITY(U,$J,358.3,41624,2)
 ;;=^5007504
 ;;^UTILITY(U,$J,358.3,41625,0)
 ;;=I69.352^^155^2061^33
 ;;^UTILITY(U,$J,358.3,41625,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41625,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff left dominant side
 ;;^UTILITY(U,$J,358.3,41625,1,4,0)
 ;;=4^I69.352
 ;;^UTILITY(U,$J,358.3,41625,2)
 ;;=^5007505
 ;;^UTILITY(U,$J,358.3,41626,0)
 ;;=I69.353^^155^2061^35
 ;;^UTILITY(U,$J,358.3,41626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41626,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc aff right nondom side
 ;;^UTILITY(U,$J,358.3,41626,1,4,0)
 ;;=4^I69.353
 ;;^UTILITY(U,$J,358.3,41626,2)
 ;;=^5007506
 ;;^UTILITY(U,$J,358.3,41627,0)
 ;;=I69.354^^155^2061^36
 ;;^UTILITY(U,$J,358.3,41627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41627,1,3,0)
 ;;=3^Hemiplga fol cerebral infrc affecting left nondom side
